首页> 外文OA文献 >Enhancement of in vitro therapeutic efficacy using combination paclitaxel and ceramide therapy using EGFR targeted biodegradable polymeric nanoparticles in ovarian cancer model

【2h】

Enhancement of in vitro therapeutic efficacy using combination paclitaxel and ceramide therapy using EGFR targeted biodegradable polymeric nanoparticles in ovarian cancer model

机译：使用EGFR靶向可生物降解聚合物纳米粒子在卵巢癌模型中使用组合紫杉醇和神经酰胺治疗的体外治疗疗效的增强

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Darshna Patel;
展开▼
作者单位

展开▼
年度 -1
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Enhanced Chemotherapeutic Efficacy of Paclitaxel Nanoparticles Co-delivered with MicroRNA-7 by Inhibiting Paclitaxel-Induced EGFR/ERK pathway Activation for Ovarian Cancer Therapy [J] . Cui Xiaojuan, Sun Ying, Shen Ming, ACS applied materials & interfaces . 2018,第9期

机译：通过抑制紫杉醇诱导的EGFR / ERK途径激活卵巢癌治疗，增强了用MicroRNA-7共递送的紫杉醇纳米粒子的化学治疗效果。卵巢癌治疗
2. Macitentan (ACT-064992), a Tissue-Targeting Endothelin Receptor Antagonist, Enhances Therapeutic Efficacy of Paclitaxel by Modulating Survival Pathways in Orthotopic Models of Metastatic Human Ovarian Cancer [J] . Sun-Jin Kim, Jang Seong Kim, Seung Wook Kim, Neoplasia: an international journal for oncology research . 2011,第2期

机译：Macitentan（ACT-064992），一种组织靶向内皮素受体拮抗剂，通过调节转移性人卵巢癌的原位模型中的存活途径来增强紫杉醇的治疗效果
3. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. [J] . Shibuya K, Komaki R, Shintani T, International Journal of Radiation Oncology, Biology, Physics . 2007,第5期

机译：用ZD6474靶向VEGFR和EGFR的靶向疗法在人非小细胞肺癌的原位模型中增强了放射治疗的疗效。
4. Paclitaxel and Ceramide Combination Therapy in Biodegradable Polymeric Nanoparticles to Overcome Multidrug Resistance in Cancer [C] . Harikrishna Devalapally, Lilian van Vlerken, Zhenfeng Duan, Controlled Release Society Annual Meeting and Exposition . 2007

机译：紫杉醇和神经酰胺联合治疗可生物降解的聚合物纳米颗粒，以克服癌症中的多药耐药性
5. Tumor hypoxia, the Warburg effect, and multidrug resistance: Modulation of hypoxia induced MDR using EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine therapy. [D] . Jabr-Milane, Lara Scheherazade. 2010

机译：肿瘤缺氧，Warburg效应和多药耐药性：使用紫杉醇/ LONIDamine疗法联合使用EGFR靶向的聚合物共混纳米载体，调节缺氧诱导的MDR。
6. Biodistribution and Pharmacokinetic Analysis of Combination Lonidamine and Paclitaxel Delivery in an Orthotopic Animal Model of Multi-drug Resistant Breast Cancer Using EGFR-Targeted Polymeric Nanoparticles [O] . Lara Milane, Zhen-feng Duan, Mansoor Amiji -1

机译：使用EGFR靶向聚合物纳米颗粒在多药物抗性乳腺癌的原位动物模型中组合Lonidamine和紫杉醇递送的生物分布和药代动力学分析
7. Macitentan (ACT-064992), a Tissue-Targeting Endothelin Receptor Antagonist, Enhances Therapeutic Efficacy of Paclitaxel by Modulating Survival Pathways in Orthotopic Models of Metastatic Human Ovarian Cancer12 [O] . Kim, Sun-Jin, Kim, Jang Seong, Kim, Seung Wook, 2011

机译：Macitentan（ACT-064992），一种针对组织的内皮素受体拮抗剂，通过调节转移性人类卵巢癌原位模型中的生存途径来提高紫杉醇的治疗效果12
8. Targeting Paclitaxel-Loaded Nanoparticles to Ovarian Cancer. [R] . Howell, S. B. 2013

机译：将紫杉醇负载的纳米粒子靶向卵巢癌。

Enhancement of in vitro therapeutic efficacy using combination paclitaxel and ceramide therapy using EGFR targeted biodegradable polymeric nanoparticles in ovarian cancer model

著录项

引文网络

相似文献

相关主题

期刊订阅